The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry

DOI: 10.1111/cge.12441
Clinical Genetics, 2015, 88, 41-8.

#	Paper	IF	Citations
22	Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. *BMC Cancer*, **2015**, 15, 215	4.8	79
21	Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. *Oncotarget*, **2016**, 7, 80465-80481	3.3	39
20	Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. *PLoS ONE*, **2016**, 11, e0161438	3.7	10
19	Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. *Breast Cancer Research and Treatment*, **2016**, 159, 245-56	4.4	20
18	The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer. *Familial Cancer*, **2016**, 15, 111-21	3	18
17	Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes. *Journal of Molecular Diagnostics*, **2017**, 19, 502-513	5.1	7
16	Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms. *Gene Therapy*, **2017**, 24, 601-609	4	3
15	Identification of pathogenic retrotransposon insertions in cancer predisposition genes. *Cancer Genetics*, **2017**, 216-217, 159-169	2.3	19
14	First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis. *BMC Cancer*, **2019**, 19, 871	4.8	8
13	Non- Variants Detected in a High-Risk Chilean Cohort With a History of Breast and/or Ovarian Cancer. *Journal of Global Oncology*, **2019**, 5, 1-14	2.6	1
12	BRCA gene mutations: A population based review. *Gene Reports*, **2019**, 15, 100380	1.4	
11	The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome families. *Genes Chromosomes and Cancer*, **2019**, 58, 657-664	5	1
10	Tumor Testing for Somatic and Germline / Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects. *Frontiers in Oncology*, **2020**, 10, 1318	5.3	3
9	Early-onset breast cancer in a woman with a germline mobile element insertion resulting in disruption: a case report. *Human Genome Variation*, **2020**, 7, 24	1.8	2
8	The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. *Cancers*, **2020**, 12,	6.6	4
7	Generation and characterization of induced pluripotent stem cells heterozygous for the Portuguese BRCA2 founder mutation. *Stem Cell Research*, **2021**, 53, 102364	1.6	1
6	Hereditary breast cancer and ancestry in the Madeira archipelago: an exploratory study. *Ecancermedicalscience*, **2021**, 15, 1261	2.7	0

5	Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment. *PeerJ*, **2017**, 5, e3046	3.1	15
4	Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment.		
3	Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of and Homologous Recombination Genes.. *Biomedicines*, **2022**, 10,	4.8	0
2	Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome. **2022**, 14, 4717		0
1	Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene.		2